T cell co-stimulation pathway

The **T cell co-stimulation pathway** refers to the network of receptor-ligand interactions that provide a critical “second signal” necessary for full T cell activation following antigen recognition by the T cell receptor (TCR)[1][2][3][4][6][9]. Without this co-stimulatory signal, TCR engagement alone usually results in T cell anergy or apoptosis, whereas productive co-stimulation amplifies T cell responses, promoting proliferation, survival, differentiation, and cytokine secretion. The pathway integrates both **co-stimulatory** and **co-inhibitory** signals, primarily mediated by cell-surface molecules belonging to the immunoglobulin superfamily (IgSF) and tumor necrosis factor receptor superfamily (TNFRSF), including members such as **CD28, CTLA-4, ICOS, 4-1BB, OX40, GITR, HVEM, CD27**, and their respective ligands[1][4][5][7][9]. The outcome of this integration determines the magnitude and quality of the T cell response. Components of this pathway are major targets in cancer immunotherapy (“immune checkpoint” blockade and co-stimulation), autoimmune disease, and transplant rejection therapies, but “T cell co-stimulation pathway” is not a molecule, receptor, or druggable protein; it is a molecular process involving several individual targets[1][2][4][5][9]. **Note:** - This is **not an individual molecule or canonical therapeutic target** (like CD28 or CTLA-4); rather, it is a pathway/process involving many protein targets. For structured data, you should identify and reference specific molecules (e.g., CD28, CTLA-4, OX40) rather than the pathway as a whole[1][7]. - If a specific molecular target is needed, select a well-defined co-stimulatory or co-inhibitory molecule from this pathway (e.g., “CD28” or “CTLA-4”) as the entry.

Other names

T cell costimulation pathwayT cell co-signaling pathwayT cell co-stimulatory pathwayT cell co-signaling system